Eric Brandt, Investment Manager at NOSHAQ, will replace Jean-Claude Muller at the next Op2Lysis Board meeting. Jean-Claude has decided to leave the governance of Op2Lysis and that of other companies for personal reasons. NOSHAQ’s support during the last Op2Lysis fundraiser has been a driving component of our funding to get closer to the initiation stage of clinical trials. Eric’s professional career during more than 12 years, in the financing of companies in the field of life sciences, will constitute a definite contribution to the Company, and in complementarity with the other members. The integration of Eric in the governance of Op2Lysis testifies to the expansion of Op2Lysis in the ecosystem of Wallonia to structure its development activities, while keeping its research activity in Caen in Normandy.
We welcome Eric to this new role. We warmly thank Jean-Claude for his essential and significant contribution since the creation of Op2Lysis.
The 6 members of the Board of Op2Lysis are now: Eric Brandt, Patrick Cassagne, Christophe Gaudin, Philippe Monteyne, Jérôme Parcq and Thierry Sempere.
We are very pleased to welcome BEANGELS and NOSHAQ on board. Together with our historical investors, they put a >1M€ investment in Op2Lysis to ensure the scale-up and the industrial development of the production processes of O2L-001 to reach the regulatory studies and to get closer to the initiation of the clinical trial.
For more information about this SEED funding, read the Press Release:
The Op2Lysis team wishes you a great and successful year 2021. We keep the pace to progress in the development of O2L-001 and to ensure the human / financials & technical ressources to treat our first ICH patients within 18 months.
Through this mini-series of articles, we want to present you our whole team and skills of each.
I am both pharmacist and toxicologist. I studied pharmacy at the University of Bordeaux and specialised in the toxicology field at the University of Paris Descartes. I worked as a Study Director at Charles River Laboratories (Evreux facility, Normandy), where I oversaw regulatory toxicology studies for pre-clinical development. I joined Op2lysis in September 2020 as a Regulatory Affairs Manager. My main mission is to develop and coordinate the regulatory strategy for our project, in collaboration with the other team members and external experts.
There was three main motivations to join Op2Lysis:
The project: I had a high interest and motivation for Op2lysis project, I am glad to be part of an innovative project and to be able to contribute to its development.
The position: through my missions I can improve both my scientific and regulatory knowledges while I develop other professional skills.
Workplace: I was attracted by the environment a start up provides with various missions and activities. By integrating a small company, I am fully involved in the decision of the company, I can support my ideas and proposition during team meetings, which make me feel useful and an active player of the project.
To my point of view the main strenghts of the technology are
Thanks to my education I have strong basis on regulatory non-clinical drug development and good scientific knowledges. In my previous position as I worked in a controlled and rigorous regulatory environment, I acquired professional skills relevant for the development of our project (project management, communication, reporting, problem solving)
Op2Lysis SAS announced the signature of a license agreement with CARLINA Technologies for exploiting its PEPTIDOTSTM technology.
Read the press release below for more information
Receipt of a decision to grant a patent from the European Patent Office for a strategic patent application related to Op2Lysis O2L-001 program for hemorrhagic stroke patients.
See the press release below
Op2Lysis receives the seal of Excellence for the development the first medical treatment dedicated to patients with intracerebral hemorrhage (EIC Accelerator – SME Phase II).
Op2Lysis project was scored as a high quality proposal in this highly competitive evaluation process. #SMEinstrument #SealOfExcellence
More Information about SME instrument: https://ec.europa.eu/programmes/horizon2020/en/h2020-section/eic-accelerator-pilot
With the support of Enterprise Europe Network, Op2lysis has been selected by EU-Japan to be part of the Biotech Cluster SME mission.
This selection will provide Op2lysis with the opportunity to attend BioJapan Expo 2019, next October. This mission will allow the company to meet with Japanese companies.
This mission comes at the right time for Op2lysis, as it will allow us to extend a network of contacts and to favour a partnership with a Japanese company in order to integrate Japan at the early stage of our clinical development.
Hemorrhagic stroke accounts for about 30% of all strokes in Japanese patients. Japan is the world’s second-largest market for hemorrhagic stroke.
With the support of the Enterprise Europe Network France, we are very proud of having been selected among many candidates for this mission. With this great opportunity, we hope to produce the best possible benefit for our development.
For more information : Click here
The second half of May was the opportunity for two important conventions in the area of hemorrhagic stroke :
Although dedicated to a broader scope, ESOC offered many presentations and sessions on hemorrhagic stroke, reinforcing the increasing activity and hope in this area as it appeared at the last International Stroke Conference in February.
Of particular interest for Op2Lysis was a presentation by Wendy Ziai on the analysis of mortality in the MISTIE (Minimally Invasive Thrombolysis in Intracerebral Hemmorhage Evacuation) trial. The primary results of this study, which were presented on last February, showed a lower rate of mortality in the minimally invasive surgery plus thrombolytic group of patients versus control group, more specifically over the first 30 days that followed symptom onset.
The more detailed analysis presented at ESOC indicated that deaths were mainly from neurological cause (60%) and consecutive to withdrawal of life support. The reduction in intracebral hematoma volume, which was the objective of the treatment tested in MISTIE, influenced favorably the maintenance of life support. These results further strengthen the rationale for the product developed by Op2Lysis for the treatment of patients with an intracerebral hematoma following an hemorrhagic stroke.
The modified Rankin Score (mRS) is used by health professionals to measure the degree of disability following a stroke in a patient. This disability scale includes 6 levels of score ranging from level 0 for patients with no symptoms to level 5 for patients with major disabilities and total loss of autonomy. A separate category, Level 6, is usually added by the medical profession for patients who do not survive their stroke.
The mRS scale, deemed reliable and easy to use, is recognised by the health authorities for the registration of a medicinal product on the market but also recognized by health insurances, since this scale also allows them to determine the cost of managing a patient based on level of disability.
It is therefore used as the primary clinical criterion in most clinical trials for the registration of new stroke treatments. Standardized interviews to obtain a mRS score are recommended every 3 months (90 days) after discharge from the hospital.
The clinical development program of O2L-001 will therefore also call on the mRS score. Our ambition is to reduce the number of patients with severe disabilities and severe socio-economic dependence.